ENDRA Life Sciences posts Q2 profit on digital asset gains ahead of merger - NDRA News | RalliesENDRA Life Sciences posts Q2 profit on digital asset gains ahead of merger
N
NDRA• Merger outlook and cost controls
- The company entered a definitive merger agreement with Noble Africa; the deal is expected to close in Q4 2026.
- ENDRA expects to complete the merger with Noble Africa in Q4 2026, subject to approvals.
- ENDRA is focused on satisfying conditions necessary to complete the merger transaction.
- The company sharply reduced R&D and sales and marketing expenses during its strategic alternatives process and pending merger.
Reported metric and analyst context
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|
| Q2 Operating Expenses | | $1.5 mln | |
- The one available analyst rating on the shares is "buy."
- The average consensus recommendation for the biotechnology & medical research peer group is "buy."
- Wall Street's median 12-month price target for ENDRA Life Sciences Inc is $25.00, about 459.3% above its August 14 closing price of $4.47.
Q2 profit driven by digital asset gains
- US thermoacoustic imaging firm's Q2 net income rose, reversing a loss from the prior year.
- Q2 operating expenses increased, but R&D and sales and marketing costs declined sharply.
- Net income was driven primarily by realized and unrealized gains from the company's digital asset treasury.
WAVE
•
